Plain-English translation of NCT07685210 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing GenSci144, a new medication designed to help treat phenylketonuria, a rare genetic condition. Researchers will give healthy adult volunteers different doses of the medication (or a placebo, which is a dummy pill with no active ingredient) to see how safe it is, how well people tolerate it, and how the body processes it.
Before this medication can be tested in patients with phenylketonuria, researchers need to understand whether it is safe and how it behaves in the human body. This early safety study in healthy volunteers is a standard first step that helps protect patients later on.
You likely qualify if…
You likely don't qualify if…
As a participant, you would visit the study site and receive a single dose of either the new medication or a placebo by mouth. Throughout the study, your blood will be drawn several times to measure how the medication moves through your body and how it affects you. The study team will carefully monitor your health and ask about any side effects you experience. This is a double-blind study, meaning neither you nor the researchers will know whether you received the medication or the placebo.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
China